Press Releases

TGA Cancellation of EndoBarrier Listing

TGA Cancellation of EndoBarrier Listing GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical technology company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, has received final cancellation notification from the...

read more

Appendix 4C: Quarter ended 30 June 2016

Appendix 4C: Quarter ended 30 June 2016 GI Dynamics, Inc. (ASX: GID) (the Company), a medical technology company that has developed an innovative device to improve outcomes for patients battling type 2 diabetes and obesity, today released its Appendix 4C — Quarterly Cash Flow Report for the...

read more

Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA

Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA Statistically and clinically significant efficacy: 1.1% absolute reduction in HbA1c Statistically and clinically significant efficacy: 7.7% reduction in body weight 34.8% of patients achieved the ADA target of HbA1c ≤ 7.0% after...

read more

Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting

Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting EndoBarrier mechanism-of-action study shows ~18 kg mean weight loss and negative correlation between fat absorption and weight loss1 EndoBarrier treatment shows reduction in hepatic fat of 81% and 6x liraglutide...

read more

EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting

EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting LEXINGTON, Massachusetts and SYDNEY, Australia – 9 June 2016 – GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative endoscopically delivered treatment for type 2 diabetes and...

read more

GI Dynamics Appoints Chief Compliance Officer

GI Dynamics Appoints Chief Compliance Officer LEXINGTON, Mass & SYDNEY, Australia – 10 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Brian Callahan...

read more

GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy

GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy LEXINGTON, Massachusetts and SYDNEY, Australia – 9 May 2016 AEST – GI Dynamics, Inc. (ASX:GID), a medical device company that develops innovative endoscopically delivered treatments for type 2 diabetes and obesity, announced new...

read more

GI Dynamics Appoints Chief Financial Officer

GI Dynamics Appoints Chief Financial Officer LEXINGTON, Massachusetts & SYDNEY, Australia – 5 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Jim...

read more

Daniel J. Moore Elected Chairman of the Board

Daniel J. Moore Elected Chairman of the Board LEXINGTON, Massachusetts & SYDNEY, Australia – 3 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, is pleased to announce that the board of...

read more

Appendix 4C Quarterly Report Quarter Ended 31 March 2016

Appendix 4C Quarterly Report Quarter Ended 31 March 2016 LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 29 April 2016 – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, releases its Appendix 4C...

read more
Page 2 of 1012345...10...Last »